News
-
NexBio, which was recently raided by the US Federal Bureau of Investigation (FBI), has announced results from a Phase 2 clinical trial of its Fludase inhaled antiviral for the treatment of influenza. According to the… Read more . . .
-
Massacheusetts biotech company Pulmatrix has secured $14 million in additional funding from its existing investors, including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund, bringing its total to $60 million. Terry… Read more . . .
-
The United States Patent and Trademark Office (USPTO) has issued US Patent No. 7,994,197, titled “Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile,” to MAP Pharmaceuticals for its… Read more . . .
-
A leading pharmaceutical company has an exciting opportunity for an experienced device engineer. This position is based in Switzerland. In this role you will: • Support and lead inhalation device development projects • Mentor fellow… Read more . . .
-
After a meeting with the FDA, MannKind Corporation has announced that the company and the agency have confirmed protocols for new efficacy and safety studies of Afrezza inhaled insulin. The original studies of Afrezza were… Read more . . .
-
Akela Pharma is looking for a buyer for its Taifun fentanyl development program after Teikoku Seiyaku returned Japanese rights to the product. The dry powder inhaler (DPI) was being developed for the treatment of breakthrough… Read more . . .
-
MAP Pharmaceuticals has hired Frederick H. Graff as VP, Commercial Operations, a position newly created in anticipation of a potential launch of the company’s Levadex inhaled dihydroergotamine (DHE) for the treatment of migraine. Graff was… Read more . . .
-
On or about September 6, 2011, United States District Court Judge William G. Young will hold a hearing to issue sanctions against InnovaSystems for contempt of court, having ruled that Innova has violated a permanent… Read more . . .
-
The US FDA has accepted the new drug application (NDA) filed by Teva on May 24, 2011 for its beclomethasone dipropionate (BDP) hydrofluoroalkane nasal spray for the treatment of seasonal allergic rhinitis (SAR) and perennial… Read more . . .
-
According to news reports, the US Federal Bureau of Investigation (FBI) has raided the San Diego, California headquarters of vaccine developer NexBio and removed papers. FBI agent Darrell Foxworth is quoted as saying that the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal